Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
StockNews.AI · 2 hours
AI Summary
Anixa announced the first patient in Cohort 5 was dosed at the highest level (1x10^7 CAR-positive cells/kg) in its FSHR-targeted CAR-T trial for recurrent ovarian cancer at Moffitt. With no dose-limiting toxicities and five patients surviving over a year (one beyond two years), the data offer an early but meaningful safety/efficacy signal that could accelerate enrollment and upcoming milestones.
Sentiment Rationale
Early-stage safety improves; OS-like signals in a hard-to-treat population could attract investor attention and potential upside if corroborated by additional cohorts.
Trading Thesis
Bullish: sustained safety and survival signals could re-rate ANIX within 6–12 months as data mature.
Market-Moving
- Progress to Cohort 5 at the highest dose is a direct data catalyst for ANIX.
- No dose-limiting toxicities reduce near-term trial risk.
- Five >12-month survivors imply potential efficacy signals in a difficult ovarian cancer population.
- Moffitt collaboration adds credibility and may speed enrollment and visibility.
Key Facts
- First patient treated in Cohort 5 of FSHR CAR-T trial.
- Dose: 1x10^7 CAR-positive cells/kg after lymphodepletion; no DLTs observed.
- Five patients survived beyond one year; one beyond two years.
- Trial at Moffitt Cancer Center (NCT05316129) evaluates lira-cel CER-T for recurrent ovarian cancer.
Companies Mentioned
- Anixa Biosciences, Inc. (ANIX): Phase 1 FSHR CAR-T (lira-cel) data progression; potential near-term catalyst if safety and signals persist.
- Moffitt Cancer Center (N/A): Collaborating institution; credible site that supports enrollment and data quality; not a public company.
Industry News
Industry News: Clinical-trial progress on a novel CAR-T for ovarian cancer; important for ANIX's pipeline value and potential upside if durability signals hold.